SynthesisInternational journal of obesity (2005)2025
The effects of fluoxetine on body weight, waist circumference, and body mass index in individuals who are overweight or have obesity: a meta-analysis of randomized controlled trials.
Synthesis in International journal of obesity (2005), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of fluoxetine administration on body weight (BW), waist circumference (WC), and body mass index (BMI) remains inconclusive, as many studies have reported contradicting results. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the impact of fluoxetine prescription on these anthropometric indices. A comprehensive systematic review was conducted in PubMed/MEDLINE, SCOPUS, Web of Science, and EMBASE for manuscripts indexed before Jun 28st, 2025. The results were computed using the DerSimonian and Laird random effects model and reported as weighted mean differences (WMD) with 95% confidence intervals (CI). The current meta-analysis included 22 RCT arms (2348 individuals: placebo = 1166; fluoxetine = 1182) on BW, 2 RCT arms (77 individuals: placebo = 39; fluoxetine = 38) on WC, and 4 RCT arms (215 individuals: placebo = 105; fluoxetine = 110) on BMI. The present meta-analysis included 22 RCT arms (2348 individuals: placebo = 1166; fluoxetine = 1182) on BW. Fluoxetine treatment significantly reduced BW (WMD: -2.095 kg, p < 0.001), with significant heterogeneity noted among the RCTs (I² = 84.7%, P < 0.001). Fluoxetine supplementation decreased BW more substantially when the dose was ≥60 mg/day (WMD: -2.759 kg, p < 0.001) compared to <60 mg/day (WMD: -1.017 kg, p = 0.001), in trials lasting ≤12 weeks (WMD: -3.000 kg, p < 0.001) versus >12 weeks (WMD: -1.114 kg, p = 0.047), and when administered to individuals living with obesity (WMD: -2.246 kg, p < 0.001) compared to those living with overweight (WMD: -1.972 kg, p < 0.001). Fluoxetine did not impact WC or BMI values. Fluoxetine administration is associated with a reduction in BW, particularly when prescribed at doses ≥60 mg/day, during short-term interventions (≤3 months), and in individuals living with obesity.
Indexed as
Identifiers
40858794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.